Antinociceptive effect of N,N-dimethyltryptamine (DMT) involving serotonergic, opioidergic, cannabinoidergic, and nitrergic systems in PGE2-induced hyperalgesia in rats

Abstract

1. Dos Santos RG, Hallak JEC. Ayahuasca: pharmacology, safety, and therapeutic effects. CNS Spectr. 2024 Nov 20;30(1):e2. 2. Bouso JC, González D, Fondevila S, Cutchet M, Fernández X, Ribeiro Barbosa PC, et al. Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of Ayahuasca: a longitudinal study. PLoS One. 2012;7(8):e42421. 3. Sarris J, Perkins D, Cribb L, Schubert V, Opaleye E, Bouso JC, et al. Ayahuasca use and reported effects on depression and anxiety symptoms: An international cross-sectional study of 11,912 consumers. Journal of Affective Disorders Reports. 2021 Apr 1;4:100098. 4. Dos Santos RG, Osório FL, Crippa JA, Hallak JE. Antidepressive and anxiolytic effects of ayahuasca: a systematic literature review of animal and human studies. Braz J Psychiatry. 2016 Mar;38(1):65–72. 5. Barker SA, McIlhenny EH, Strassman R. A critical review of reports of endogenous psychedelic N, N-dimethyltryptamines in humans: 1955-2010. Drug Test Anal. 2012 Jul-Aug;4(7-8):617–35. 6. Jiménez JH, Bouso JC. Significance of mammalian N, N-dimethyltryptamine (DMT): A 60-year-old debate. J Psychopharmacol. 2022 Aug;36(8):905–19. 7. Schimmelpfennig J, Jankowiak-Siuda K. Unique biological and physiological properties of endogenous N, N-dimethyltryptamine from the perspective of functioning of the nervous system. Neuropsychiatria i Neuropsychologia/Neuropsychiatry and Neuropsychology. 2023;18(1):1–10. 8. Nardai S, László M, Szabó A, Alpár A, Hanics J, Zahola P, et al. N,N-dimethyltryptamine reduces infarct size and improves functional recovery following transient focal brain ischemia in rats. Exp Neurol. 2020 May;327:113245. 9. Morales-Garcia JA, Calleja-Conde J, Lopez-Moreno JA, Alonso-Gil S, Sanz-SanCristobal M, Riba J, et al. N,N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo. Transl Psychiatry. 2020 Sep 28;10(1):331. 10. Barker SA. N, N-dimethyltryptamine (DMT) in rodent brain: Concentrations, distribution, and recent pharmacological data. Prog Neuropsychopharmacol Biol Psychiatry. 2025 Mar 20;137:111259. 11. Cameron LP, Benson CJ, Dunlap LE, Olson DE. Effects of N, N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression. ACS Chem Neurosci. 2018 Jul 18;9(7):1582–90. 12. Kooijman NI, Willegers T, Reuser A, Mulleners WM, Kramers C, Vissers KCP, et al. Are psychedelics the answer to chronic pain: A review of current literature. Pain Pract. 2023 Apr;23(4):447–58. 13. Machado PD, Fonseca FCS, Azevedo MC, Filho SAV, Cavalcanti AD, Santos ODH, et al. Antinociceptive effects of Psychotria viridis Ruiz & Pav. on carrageenan-induced hyperalgesia in rats. Curr Top Pharmacol. 27: 1–8. 14. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 1983 Jun;16(2):109–10. 15. RANDALL LO, SELITTO JJ. A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther. 1957 Sep 1;111(4):409–19. 16. Soares-Santos RR, Machado DP, Romero TL, Duarte IDG. Nitric oxide and potassium channels but not opioid and cannabinoid receptors mediate tramadol-induced peripheral antinociception in rat model of paw pressure withdrawal. Can J Physiol Pharmacol. 2024 Mar 1;102(3):218–27. 17. Wall PD, Melzack R, McMahon SB, Koltzenburg M, Tracey I, Turk DC. Wall and Melzack's textbook of pain. (No Title). 2006. 18. Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther. 2004 Aug;103(2):147–66. 19. Cozzi NV, Gopalakrishnan A, Anderson LL, Feih JT, Shulgin AT, Daley PF, et al. Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter. J Neural Transm (Vienna). 2009 Dec;116(12):1591–9. 20. Halberstadt AL. Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behav Brain Res. 2015 Jan 15;277:99–120. 21. Nagai F, Nonaka R, Satoh Hisashi Kamimura K. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol. 2007 Mar 22;559(2-3):132–7. 22. Halman A, Kong G, Sarris J, Perkins D. Drug-drug interactions involving classic psychedelics: A systematic review. J Psychopharmacol. 2024 Jan;38(1):3–18. 23. Diniz DA, Petrocchi JA, Navarro LC, Souza TC, Castor MG, Perez AC, et al. Serotonin induces peripheral mechanical antihyperalgesic effects in mice. Eur J Pharmacol. 2015 Nov 15;767:94–7. 24. Carbonaro TM, Gatch MB. Neuropharmacology of N,N-dimethyltryptamine. Brain Res Bull. 2016 Sep;126(Pt 1):74–88. 25. Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB, Ruoho AE. The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science. 2009 Feb 13;323(5916):934–7. 26. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, et al. Predicting new molecular targets for known drugs. Nature. 2009 Nov 12;462(7270):175–81. 27. Riba J, McIlhenny EH, Valle M, Bouso JC, Barker SA. Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca. Drug Test Anal. 2012 Jul-Aug;4(7-8):610–6. 28. Ruffing DM, Domino EF. Effects of selected opioid agonists and antagonists on DMT- and LSD-25-induced disruption of food-rewarded bar pressing behavior in the rat. Psychopharmacology (Berl). 1981;75(3):226–30. 29. Romero TR, Pacheco Dda F, Duarte ID. Xylazine induced central antinociception mediated by endogenous opioids and μ-opioid receptor, but not δ-or κ-opioid receptors. Brain Res. 2013 Apr 19;1506:58–63. 30. Petrocchi JA, de Almeida DL, Paiva-Lima P, Queiroz-Junior C, Caliari MV, Duarte IDG, et al. Peripheral antinociception induced by ketamine is mediated by the endogenous opioid system. Eur J Pharmacol. 2019 Dec 15;865:172808. 31. Vučković S, Srebro D, Vujović KS, Vučetić Č, Prostran M. Cannabinoids and Pain: New Insights From Old Molecules. Front Pharmacol. 2018 Nov 13;9:1259. 32. Romero TR, Resende LC, Guzzo LS, Duarte ID. CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system. Anesth Analg. 2013 Feb;116(2):463–72. 33. Veress G, Meszar Z, Muszil D, Avelino A, Matesz K, Mackie K, et al. Characterisation of cannabinoid 1 receptor expression in the perikarya, and peripheral and spinal processes of primary sensory neurons. Brain Struct Funct. 2013 May;218(3):733–50. 34. Anand U, Otto WR, Sanchez-Herrera D, Facer P, Yiangou Y, Korchev Y, et al. Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons. Pain. 2008 Sep 15;138(3):667–80. 35. Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci. 2004 Jan 30;74(11):1317–24. 36. Anand P, Whiteside G, Fowler CJ, Hohmann AG. Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev. 2009 Apr;60(1):255–66. 37. Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, et al. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):3093–8. 38. Welch SP. Interaction of the cannabinoid and opioid systems in the modulation of nociception. Int Rev Psychiatry. 2009 Apr;21(2):143–51. 39. Romero TR, Resende LC, Duarte ID. The neuronal NO synthase participation in the peripheral antinociception mechanism induced by several analgesic drugs. Nitric Oxide. 2011 Nov 30;25(4):431–5. 40. Reis GM, Ramos MA, Pacheco Dda F, Klein A, Perez AC, Duarte ID. Endogenous cannabinoid receptor agonist anandamide induces peripheral antinociception by activation of ATP-sensitive K+ channels. Life Sci. 2011 Apr 11;88(15-16):653–7. 41. Duarte ID, Ferreira SH. The molecular mechanism of central analgesia induced by morphine or carbachol and the L-arginine-nitric oxide-cGMP pathway. Eur J Pharmacol. 1992 Oct 6;221(1):171–4. 42. Durate ID, Lorenzetti BB, Ferreira SH. Peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway. Eur J Pharmacol. 1990 Sep 21;186(2-3):289–93. 43. Rodrigues AR, Duarte ID. The peripheral antinociceptive effect induced by morphine is associated with ATP-sensitive K(+) channels. Br J Pharmacol. 2000 Jan;129(1):110–4. 44. Soares AC, Duarte ID. Dibutyryl-cyclic GMP induces peripheral antinociception via activation of ATP-sensitive K(+) channels in the rat PGE2-induced hyperalgesic paw. Br J Pharmacol. 2001 Sep;134(1):127–31. 45. Aguiar DD, Petrocchi JA, da Silva GC, Lemos VS, Castor MGME, Perez AC, et al. Participation of the cannabinoid system and the NO/cGMP/KATP pathway in serotonin-induced peripheral antinociception. Neurosci Lett. 2024 Jan 1;818:137536. 46. Amarante LH, Alves DP, Duarte ID. Study of the involvement of K+ channels in the peripheral antinociception of the kappa-opioid receptor agonist bremazocine. Eur J Pharmacol. 2004 Jun 28;494(2-3):155–60. 47. Pacheco Dda F, Pacheco CM, Duarte ID. Peripheral antinociception induced by δ-opioid receptors activation, but not μ- or κ-, is mediated by Ca²⁺-activated Cl⁻ channels. Eur J Pharmacol. 2012 Jan 15;674(2-3):255–9. 48. Pacheco Dda F, Pacheco CM, Duarte ID. δ-Opioid receptor agonist SNC80 induces central antinociception mediated by Ca2+ -activated Cl- channels. J Pharm Pharmacol. 2012 Aug;64(8):1084–9. 49. Romero TR, Pacheco Dda F, Duarte ID. Probable involvement of Ca(2+)-activated Cl(-) channels (CaCCs) in the activation of CB1 cannabinoid receptors. Life Sci. 2013 May 2;92(14-16):815–20. 50. Winstock AR, Kaar S, Borschmann R. Dimethyltryptamine (DMT): prevalence, user characteristics and abuse liability in a large global sample. J Psychopharmacol. 2014 Jan;28(1):49–54. 51. Savić Vujović K, Jotić A, Medić B, Srebro D, Vujović A, Žujović J,